Taghinia Amir H, Shapiro Fred E, Slavin Sumner A
Boston, Mass. From the Division of Plastic Surgery and the Department of Anesthesia, Beth Israel-Deaconess Medical Center and Harvard Medical School.
Plast Reconstr Surg. 2008 Jan;121(1):269-276. doi: 10.1097/01.prs.0000293867.05857.90.
Dexmedetomidine is an alpha2-agonist anesthetic with several properties that are advantageous in aesthetic facial surgery. By attenuating sympathetic nervous system activity, it induces sedation and analgesia while lowering blood pressure and preventing pain-induced hemodynamic fluctuations. It spares the respiratory drive and decreases the need for supplemental oxygen, thus reducing the fire risk of electrocautery. It decreases narcotic use, thereby further improving respiratory safety and decreasing postoperative nausea and vomiting. This retrospective study evaluated the safety and efficacy of dexmedetomidine in rhytidectomy.
Records were reviewed for 155 consecutive face lifts performed under sedation by one surgeon over 3.5 years. Intraoperative and postoperative parameters and outcomes were compared for 78 patients sedated with dexmedetomidine (dexmedetomidine group) and 77 sedated without dexmedetomidine (no-dexmedetomidine group).
Intraoperatively, the dexmedetomidine group had lower mean systolic and diastolic blood pressures and heart rate (p < 0.001). Fewer dexmedetomidine group patients had oxygen desaturation below 92 percent (p < 0.05) and fewer required antihypertensives (p < 0.01), although more required vasopressors (p < 0.01). The dexmedetomidine patients needed less midazolam (p < 0.01) and fentanyl (p < 0.001). Postoperatively, the dexmedetomidine group again had lower mean systolic and diastolic blood pressures and heart rate (p < 0.001). In addition, fewer patients in this group needed postoperative antiemetics (p < 0.05). Immediate postoperative hematomas occurred in two patients in the dexmedetomidine group and one patient in the no-dexmedetomidine group.
Dexmedetomidine lowered blood pressure, decreased the frequency of oxygen desaturations, and reduced narcotic, anxiolytic, and antiemetic use. When compared with conventional sedation, dexmedetomidine appears to improve anesthetic safety and efficacy for rhytidectomy patients.
右美托咪定是一种α2肾上腺素能激动剂麻醉药,具有多种有利于面部美容手术的特性。通过减弱交感神经系统活动,它可诱导镇静和镇痛,同时降低血压并预防疼痛引起的血流动力学波动。它不影响呼吸驱动,减少了补充氧气的需求,从而降低了电灼的火灾风险。它减少了麻醉药物的使用,从而进一步提高了呼吸安全性并减少了术后恶心和呕吐。这项回顾性研究评估了右美托咪定在除皱术中的安全性和有效性。
回顾了一位外科医生在3.5年内在镇静下连续进行的155例面部提升手术的记录。比较了78例使用右美托咪定镇静的患者(右美托咪定组)和77例未使用右美托咪定镇静的患者(未用右美托咪定组)的术中及术后参数和结果。
术中,右美托咪定组的平均收缩压、舒张压和心率较低(p<0.001)。右美托咪定组中氧饱和度低于92%的患者较少(p<0.05),需要使用抗高血压药物的患者较少(p<0.01),尽管需要使用血管升压药的患者较多(p<0.01)。使用右美托咪定的患者需要的咪达唑仑较少(p<0.01)和芬太尼较少(p<0.001)。术后,右美托咪定组的平均收缩压、舒张压和心率再次较低(p<0.001)。此外,该组中需要术后使用止吐药的患者较少(p<0.05)。右美托咪定组有2例患者术后立即出现血肿,未用右美托咪定组有1例患者出现血肿。
右美托咪定降低了血压,减少了氧饱和度降低的频率,并减少了麻醉药、抗焦虑药和止吐药的使用。与传统镇静相比,右美托咪定似乎提高了除皱术患者的麻醉安全性和有效性。